Teva Pharmaceutical Industries (TEVA) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $34.44 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: generic medicines (55.0%).
Teva is a global biopharmaceutical company with ~34,000 employees across 57 markets, operating US, Europe, and International Markets segments. Generic medicines were 55% of 2025 total revenues ($9.4B); key branded products include AUSTEDO (tardive dyskinesia/Huntington's), AJOVY... Read more
Sell if holding. Analyst target reached at $34.44 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: generic medicines (55.0%). Chart setup: RSI 44 mid-range, Bollinger mid-band. Score 5.6/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Teva Pharmaceutical Industries
Latest news
- Earnings call transcript: Teva beats Q1 2026 forecasts, stock surges 7.5% - Investing.com — Investing.com positive
- Teva Pharmaceutical (TEVA) Reports Strong Q1 Earnings, Beats Exp - GuruFocus — GuruFocus positive
- Teva Surges As Its New Growth Strategy Hits A Key Inflection Point - Investor's Business Daily — Investor's Business Daily positive
- Teva Surges As New Strategy Hits An Inflection Point - Investor's Business Daily — Investor's Business Daily positive
- Teva (TEVA) Announces Acquisition of Emalex Biosciences - GuruFocus — GuruFocus positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductgeneric medicines55%10-K Item 1A: 'total revenues from sales of our generic medicines in all our business segments were $9,421 million, or 55% of our total revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $34.44 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: generic medicines (55.0%). Chart setup: RSI 44 mid-range, Bollinger mid-band. Prior stop was $32.55. Score 5.6/10, moderate confidence.
Take-profit target: $35.04 (+1.6% upside). Prior stop was $32.55. Stop-loss: $32.55.
Concentration risk — Product: generic medicines (55.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.1): -1.5.
Teva Pharmaceutical Industries trades at a P/E of 25.4 (forward 11.0). TrendMatrix value score: 6.4/10. Verdict: Sell.
7 analysts cover TEVA with a consensus score of 4.1/5. Average price target: $40.
What does Teva Pharmaceutical Industries do?Teva is a global biopharmaceutical company with ~34,000 employees across 57 markets, operating US, Europe, and...
Teva is a global biopharmaceutical company with ~34,000 employees across 57 markets, operating US, Europe, and International Markets segments. Generic medicines were 55% of 2025 total revenues ($9.4B); key branded products include AUSTEDO (tardive dyskinesia/Huntington's), AJOVY (migraine), and UZEDY (schizophrenia/BD-1).